1,055,409 Shares in Perspective Therapeutics, Inc. $CATX Bought by Yu Fan

Yu Fan purchased a new position in shares of Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,055,409 shares of the company’s stock, valued at approximately $4,401,000. Perspective Therapeutics makes up about 4.5% of Yu Fan’s portfolio, making the stock its 6th biggest holding.

A number of other large investors have also recently added to or reduced their stakes in the company. ADAR1 Capital Management LLC grew its position in shares of Perspective Therapeutics by 687.2% in the 1st quarter. ADAR1 Capital Management LLC now owns 749,335 shares of the company’s stock valued at $3,125,000 after acquiring an additional 654,142 shares during the period. Quantinno Capital Management LP bought a new stake in shares of Perspective Therapeutics in the 1st quarter valued at about $273,000. Commodore Capital LP bought a new stake in shares of Perspective Therapeutics in the 1st quarter valued at about $26,424,000. Octagon Capital Advisors LP acquired a new stake in Perspective Therapeutics in the 1st quarter valued at about $3,301,000. Finally, Affinity Asset Advisors LLC lifted its stake in Perspective Therapeutics by 954.9% in the 1st quarter. Affinity Asset Advisors LLC now owns 3,164,582 shares of the company’s stock valued at $13,196,000 after purchasing an additional 2,864,582 shares during the last quarter. Institutional investors and hedge funds own 54.66% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently commented on CATX. BTIG Research reiterated a “buy” rating on shares of Perspective Therapeutics in a report on Friday. Wedbush restated an “outperform” rating and issued a $11.00 price objective on shares of Perspective Therapeutics in a research note on Tuesday, May 5th. Eight analysts have rated the stock with a Buy rating, According to data from MarketBeat, Perspective Therapeutics currently has an average rating of “Buy” and a consensus price target of $12.62.

Perspective Therapeutics Stock Up 1.8%

CATX stock opened at $2.87 on Wednesday. Perspective Therapeutics, Inc. has a one year low of $1.96 and a one year high of $6.16. The company has a fifty day moving average price of $3.27 and a two-hundred day moving average price of $3.90.

Perspective Therapeutics (NYSEAMERICAN:CATX) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.04. The company had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.16 million. Perspective Therapeutics had a negative net margin of 17,982.69% and a negative return on equity of 42.33%. Research analysts forecast that Perspective Therapeutics, Inc. will post -1.1 EPS for the current year.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.